The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens

Basit Öğe Kaydı
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorCoskun, Ugur
dc.contributor.authorGumus, Mahmut
dc.contributor.authorDane, Faysal
dc.contributor.authorOzkan, Metin
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorAlkis, Necati
dc.date.accessioned2024-04-24T17:14:47Z
dc.date.available2024-04-24T17:14:47Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractThere is no established standard salvage chemotherapy in the second-line setting for patients with advanced gastric cancer (AGC) pre-treated with platinum and taxane-based chemotherapy. Our study aims to evaluate the safety and efficacy of FOLFIRI regimen (irinotecan with leucovorin and bolus and continuous infusion with 5-fluorouracil) as a salvage chemotherapy regimen in patients with AGC. Medical records of 97 patients with AGC who received second-line FOLFIRI regimen between March 2006 and February 2011 were examined. Complete and partial responses were observed in 3 (3.1%) and 23 (23.7%) patients, respectively. The median time to progression (TTP) was 3.5 months (95% CI: 2.4-4.6) and the median overall survival (OS) was 10.5 months (95% CI: 8.8-12.2). The most common observed grade 3/4 toxicities were neutropenia (23.7%), diarrhea (6.2%), and stomatitis (5.2%). FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes.en_US
dc.identifier.doi10.1179/1973947812Y.0000000020
dc.identifier.endpage220en_US
dc.identifier.issn1120-009X
dc.identifier.issue4en_US
dc.identifier.pmid23040686
dc.identifier.scopus2-s2.0-84866249019
dc.identifier.scopusqualityQ3
dc.identifier.startpage217en_US
dc.identifier.urihttps://doi.org/10.1179/1973947812Y.0000000020
dc.identifier.urihttps://hdl.handle.net/11468/18193
dc.identifier.volume24en_US
dc.identifier.wosWOS:000307013400007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherManey Publishingen_US
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdvanced Gastric Canceren_US
dc.subjectSalvage Therapyen_US
dc.subjectFolfiri Regimenen_US
dc.titleThe efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimensen_US
dc.titleThe efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu